Interim Analysis Results Expected Second Half 2020 Topline Results Expected First Half 2021 Based on the Currently-Planned Sample Size NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a...
MALVERN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), ), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases,...
— 93 Percent of Patients Treated with Investigational KTE-X19 Achieved Response, Including 67 Percent with a Complete Response — — Findings Support Regulatory Filings for Kite’s Second CAR T Cell Therapy — — Data Presented at American...
Vedanta Biosciences, Inc. (Vedanta Biosciences, Vedanta or the Company), a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced the initiation of a...
Mark Terry for Biospace writes: It was, as usual, a pretty busy week in clinical trial news. Here’s a look. ASLAN Pharmaceuticals announced positive preliminary data from the lowest dose cohort of its trial of ASLAN004 for moderate-to-severe atopic dermatitis....
Email
Text